Denise Engelbrecht Zantut-Wittmann

Prof. Dr. Denise Engelbrecht Zantut-Wittmann


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2014 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
FMFrederico F. R. Maia
Frederico F. R. Maia
PMPatrícia S. Matos
Patrícia S. Matos
EPElizabeth J. Pavin
Elizabeth J. Pavin
DZDenise Engelbrecht Zantut-Wittmann
Denise Engelbrecht Zantut-Wittmann

1 November 2005 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
DZDenise Engelbrecht Zantut-Wittmann
Denise Engelbrecht Zantut-Wittmann
CRCelso D. Ramos
Celso D. Ramos
ASAllan O. Santos
Allan O. Santos
MLMarcelo M.O. Lima
Marcelo M.O. Lima
APAnita D. Panzan
Anita D. Panzan
ECEdwaldo E. Camargo
Edwaldo E. Camargo
Several factors may interfere with the success rate of radioiodine therapy (RIT) in Graves' disease. Our aim was to evaluate, retrospectively, some of these factors in the outcome of RIT. Patient gender, age at diagnosis, ophthalmopathy, disease duration, thyroid size, drug used as clinical treatment, thionamide withdrawal period during RIT preparation, FT4, TSH and [99mTc]pertechnetate thyroid uptake prior to RIT were studied as potential interference factors for RIT success. Eighty-two Graves' disease patients were submitted to RIT after thionamide treatment failure. Prior to RIT, 67 patients were receiving methimazole and 15 propylthiouracil. Thirty-three patients received thionamides during RIT; in 49 patients the medication was withdrawn for 2–30 days. [99mTc]pertechnetate thyroid uptake was determined before RIT. Fixed doses of 370 MBq of [131I]iodide were administered to all patients. Eleven patients became euthyroid; 40 became hypothyroid and 31 remained hyperthyroid. There was no association between outcome and age at diagnosis, gender, ophthalmopathy, pre-RIT FT4, TSH, antithyroid antibodies or thyrostatic drug. Multiple logistic regression showed higher probability of treatment success in patients with thyroid mass <53 g (odds ratio (OR)=8.9), with pre-RIT thyroid uptake <12.5% (OR=4.1) and in patients who withdrew thionamide before RIT (OR=4.9). Fixed doses of 370 MBq of radioiodine seem to be practical and effective for treating Graves' disease patients with [99mTc]pertechnetate uptake <12.5% and thyroid mass <53 g. This treatment is clearly not recommended for patients with large goitre. In contrast to what could be expected, patients with a high pre-RIT thyroid uptake presented a higher rate of RIT failure.

22 March 2011 in Head & Neck Oncology
Verified
Journal Article
Open access
PDF file
FMFrederico Fr Maia
Frederico Fr Maia
PMPatrícia S Matos
Patrícia S Matos
BSBradley P Silva
Bradley P Silva
APAna T Pallone
Ana T Pallone
EPElizabeth J Pavin
Elizabeth J Pavin
DZDenise Engelbrecht Zantut-Wittmann
Denise Engelbrecht Zantut-Wittmann
This study aimed to evaluate clinical, laboratory, ultrasound (US) and scintigraphyc parameters in thyroid nodule and to develop an auxiliary model for clinical application in the diagnosis of malignancy.

1 June 2012 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
AMArnaldo Moura-Neto
Arnaldo Moura-Neto
CMCamila Mosci
Camila Mosci
ASAllan O. Santos
Allan O. Santos
BABarbara J. Amorim
Barbara J. Amorim
MLMariana C. L. de Lima
Mariana C. L. de Lima
DZDenise Engelbrecht Zantut-Wittmann
Denise Engelbrecht Zantut-Wittmann
Purpose To investigate the factors influencing the success rate in a fixed, 15 mCi approach for treatment of Graves’ hyperthyroidism. Material and Methods The thyroid function outcome (hyperthyroidism or euthyroidism/hypothyroidism) was verified at least 1 year after radioiodine therapy (RIT) retrospectively and compared with presenting clinical characteristics and pre-RIT parameters in 87 patients treated with 131I-iodide for Graves’ disease in a tertiary care center. Results After RIT, 16 patients (18.4%) became euthyroid, 54 patients (62.1%) became hypothyroid, and 17 (19.5%) remained hyperthyroid. We found no statistically significant association between thyroid function outcome and gender (P = 0.50), ophthalmopathy (P = 0.69), drug used (methimazole or propylthiouracil; P = 1.00), maintenance or withdrawal of thionamides pre-RIT (P = 0.98), or 99mTc sodium pertechnetate thyroid uptake prior to RIT (P = 0.75). The only variable associated with the success rate was thyroid mass <62 g (P < 0.001). Conclusions Our study has shown that a fixed 15 mCi approach for treatment of Graves’ disease was effective, but high failure rates were observed in patients presenting larger goiters, particularly those with estimated thyroid mass >62 g.

7 June 2015 in Endocrine
Verified
Journal Article
Closed access
PDF file
ANArnaldo Moura Neto
Arnaldo Moura Neto
MPMaria Candida Ribeiro Parisi
Maria Candida Ribeiro Parisi
SASarah Monte Alegre
Sarah Monte Alegre
EPElizabeth Joao Pavin
Elizabeth Joao Pavin
MTMarcos Antonio Tambascia
Marcos Antonio Tambascia
DZDenise Engelbrecht Zantut-Wittmann
Denise Engelbrecht Zantut-Wittmann

1 January 2012 in Clinics
Verified
Journal Article
Open access
FMFrederico F. R. Maia
Frederico F. R. Maia
DZDenise Engelbrecht Zantut-Wittmann
Denise Engelbrecht Zantut-Wittmann
Although fine-needle aspiration cytology is considered to be the reference method for evaluating thyroid nodules, the results are inaccurate in approximately 10-30% of cases. Several studies have attempted to predict the risk of malignancy in thyroid nodules based on age, nodularity, thyrotropin values, thyroid autoimmune disease, hot/cold nodule status, and ultrasound parameters. However, no consensus has been found, and none of these parameters has significantly affected patient management. The management of indeterminate thyroid nodules and re-biopsies of nodules with initially benign cytological results remain important and controversial topics of discussion. The Bethesda cytological system and several studies on the use of molecular markers to predict malignancy from cytological samples of thyroid nodules need further clarification. More in-depth discussions among and continuous education of the specialists involved in treating thyroid disease are necessary to improve the management of these patients. This review aims to examine the clinical, laboratory, ultrasound, and scintigraphic parameters that can be used for thyroid nodule management.